This article is more than 5 years old. Information may no longer be current.
Test identified ESBL-producing bacteria quickly
Click Here to Manage Email Alerts
DENVER — The use of an extended-spectrum beta-lactamase, or ESBL, NDP test accurately identified 100% of blood cultures with Enterobacteriaceae that produced ESBL in 20 minutes, according to a presentation here at the 2013 Interscience Conference on Antimicrobial Agents and Chemotherapy.
“It is of utmost importance to know, as soon as possible, if the bacteria present in patients with septicemia will be sensitive or resistant to the empiric therapy initiated,” Laurent Dortet, PhD, PharmD, of the Institut National de la Santé et de la Recherché Médicale (INSERM) in Paris, told Infectious Disease News. “The rate of multidrug-resistant bacteria rose in the last decade and, consequently, we have to detect them as early as possible to adapt the antibiotic therapy.”
From November 2012 to May 2013, Dortet and colleagues evaluated 96 successive blood cultures that were positive for Gram-negative bacteria. The ESBL NDP test was performed on the 96 cultures, and the results were compared with results obtained using the double disk diffusion technique. The bacteria were identified using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF).
Eighteen cultures were infected with ESBL-producing Enterobacteriaceae. Fifteen were Escherichia coli and three were Klebsiellapneumoniae. The remaining 78 were negative on the ESBL NDP test. These results were 100% correlated with the results of the double disk diffusion method. The results of the ESBL NDP test were available within 20 minutes, whereas the results of the double disk diffusion method were available within 24 hours.
“These multidrug-resistant, ESBL-producing, bacteria strains are increasingly reported worldwide and are not only found at the hospital, but also in the community,” Dortet said. “In our clinical practice, we have routinely implemented the test and, consequently, have the results at day 0, meaning we gain 24 to 48 hours to adapt the antibiotic therapy if necessary.”
For more information:
Dortet L. #D-121. Presented at: ICAAC 2013; Sept. 10-13; Denver.
Laurent Dortet,Pharmd, PhD, can be reached at Laurent.dortet@bct.aphp.fr.
Disclosure: Dortet reports no relevant financial disclosures.